3 Fundamentally Strong Biotechnology Stocks in India
- August 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Biotechnology stocks. Biocon Ltd CMP Rs 414.31 | PE 161.84 | ROE 1.14%. Divi’s Laboratories Ltd PE 77.37. Laurus Labs Ltd PE 89.54.
Quick Answer
Three biotechnology stocks in India are Biocon Ltd (MCap Rs 67,518 Cr, PE 161.84, ROE 1.14%), Divi’s Laboratories Ltd (MCap Rs 2.26L Cr, PE 77.37, ROE 15.32%), and Laurus Labs Ltd (MCap Rs 97,634 Cr, PE 89.54, ROE 16.77%). Each covers a distinct sub-segment of the biotechnology sector. Verify all data at nseindia.com before investing.
Identifying the right biotechnology stocks in India requires looking beyond short-term price movements to balance sheet strength, earnings quality and sector positioning. Track the Nifty Pharma index alongside individual stock analysis for a complete view of biotechnology sector momentum.
This article covers three biotechnology stocks in India with key financial metrics sourced from publicly available exchange disclosures. Verify every data point at nseindia.com or bseindia.com before making any investment decision.
Click Here – Get Free Investment Predictions
What Are Biotechnology Stocks in India?
Biotechnology stocks in India are shares of companies that develop and manufacture biopharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract research and manufacturing services. India’s pharmaceutical and biotech sector is one of the world’s largest generic drug suppliers and is building a significant presence in biosimilars for global markets.
Budget 2026-27 Impact on Biotechnology Stocks in India
The Union Budget 2026-27 shaped the investment environment for biotechnology stocks in India through these sector-relevant provisions:
- PLI for pharmaceuticals and medical devices includes API and biosimilar manufacturers.
- Biologics and biosimilar manufacturing investment supported by government R&D incentives.
- Export promotion for Indian pharmaceutical products to regulated markets like the US and EU.
- New drug approval pathway simplification reduces time-to-market for biosimilars.
- Biopharmaceutical capacity building as part of Atmanirbhar Bharat for critical medicines.
3 Fundamentally Strong Biotechnology Stocks in India: Key Data
| Company | CMP (Rs) | MCap (Rs Cr) | PE | PB | ROE | EPS TTM (Rs) | Div. Yield |
|---|---|---|---|---|---|---|---|
| Biocon Ltd (NSE: BIOCON) | Rs 414.31 | 67,518 | 161.84 | 1.96 | 1.14% | 2.56 | 0.12% |
| Divi’s Laboratories Ltd (NSE: DIVISLAB) | Rs 8524.63 | 2.26L | 77.37 | 13.50 | 15.32% | 110.18 | 0.35% |
| Laurus Labs Ltd (NSE: LAURUSLABS) | Rs 1806.92 | 97,634 | 89.54 | 18.42 | 16.77% | 20.18 | 0.11% |
Verify all figures at nseindia.com before investing.
1. Biocon Ltd (NSE: BIOCON)
Biocon Ltd, founded in 1978 and headquartered in Bengaluru, is one of three biotechnology stocks in India covered here. It trades at Rs 414.31 with MCap Rs 67,518 Cr, PE 161.84 (industry avg 37.30), ROE 1.14%, EPS TTM Rs 2.56, BV Rs 211.51 and dividend yield 0.12%.
The debt-to-equity is 0.45 and price-to-book 1.96. Verify all data at nseindia.com or bseindia.com before investing in this or any other stock.
2. Divi’s Laboratories Ltd (NSE: DIVISLAB)
Divi’s Laboratories Ltd, founded in 1990 and headquartered in Hyderabad, is one of three biotechnology stocks in India covered here. It trades at Rs 8524.63 with MCap Rs 2.26L Cr, PE 77.37 (industry avg 37.30), ROE 15.32%, EPS TTM Rs 110.18, BV Rs 631.38 and dividend yield 0.35%.
The debt-to-equity is 0.00 and price-to-book 13.50. Verify all data at nseindia.com or bseindia.com before investing in this or any other stock.
Compare Biotechnology Stocks by PE, ROE and Dividend Yield on the Univest Screener
3. Laurus Labs Ltd (NSE: LAURUSLABS)
Laurus Labs Ltd, founded in 2005 and headquartered in Hyderabad, is one of three biotechnology stocks in India covered here. It trades at Rs 1806.92 with MCap Rs 97,634 Cr, PE 89.54 (industry avg 37.30), ROE 16.77%, EPS TTM Rs 20.18, BV Rs 98.09 and dividend yield 0.11%.
The debt-to-equity is 0.48 and price-to-book 18.42. Verify all data at nseindia.com or bseindia.com before investing in this or any other stock.
Download the Univest iOS App or Univest Android App to track these biotechnology stocks in India with live prices and exchange-sourced research.
Benefits of Investing in Fundamentally Strong Biotechnology Stocks
- Earnings consistency: biotechnology stocks in India with strong PE, ROE and EPS metrics have historically delivered more predictable earnings growth than low-quality sector peers.
- Lower downside risk: Fundamentally strong biotechnology stocks in India with manageable debt and positive free cash flow tend to recover faster from market corrections.
- Dividend income potential: Several biotechnology stocks in India with strong fundamentals maintain consistent dividend track records alongside capital appreciation potential.
- Index inclusion benefits: Large-cap biotechnology stocks in India in major indices receive mandatory passive flows from index funds and ETFs.
- Regulatory moat: Established biotechnology stocks in India with proven governance records typically have easier access to capital markets.
Risks of Investing in Biotechnology Stocks
- Sector cyclicality: Biotechnology stocks can face multi-quarter earnings pressure during economic downturns or policy headwinds.
- Valuation compression: High-PE biotechnology stocks in India can de-rate sharply when earnings disappoint or when sector sentiment turns.
- Competition and disruption: Technology shifts and competitive dynamics can erode market share or pricing power of biotechnology stocks in India.
- Regulatory changes: Policy shifts in taxation, duties or sector regulation can affect profitability of biotechnology stocks in India with limited advance warning.
- Global linkages: Commodity prices, exchange rates and global demand shifts affect export-linked biotechnology stocks in India earnings significantly.
How to Choose Fundamentally Strong Biotechnology Stocks
- Screen PE ratios against the industry average; any premium PE among biotechnology stocks in India requires earnings growth justification
- Target ROE consistently above 12% for at least three consecutive years to confirm durable profitability
- Check debt-to-equity below 1 for most biotechnology stocks in India; financial sector biotechnology stocks in India will naturally carry higher leverage
- Verify dividend payment consistency as a management confidence signal in forward free cash flow
- Review latest quarterly results to confirm fundamentals are trending in the right direction
Conclusion
Biocon Ltd, Divi’s Laboratories Ltd and Laurus Labs Ltd are three biotechnology stocks in India covering distinct angles of the biotechnology sector. Biocon Ltd trades at Rs 414.31 with PE 161.84 and ROE 1.14%; Divi’s Laboratories Ltd at Rs 8524.63 with PE 77.37; and Laurus Labs Ltd at Rs 1806.92 with PE 89.54. Each stock carries distinct risks. This article is for educational purposes only. Consult a SEBI-registered financial advisor before investing in biotechnology stocks in India or any other security.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs
Is Biocon a good biotech stock?
Ans. Biocon is India’s largest publicly listed biotech company with a strong biosimilars pipeline for the US and EU markets. Its current PE of 161.84 reflects low near-term earnings as it invests in biosimilar launches. The long-term thesis depends on biosimilar market penetration.
What does Divi’s Laboratories manufacture?
Ans. Divi’s Laboratories is India’s largest API manufacturer by revenue, producing custom synthesis chemicals and nutraceuticals for global pharma companies. It supplies APIs for some of the world’s bestselling medicines, including carotenoids and high-value active ingredients.
What is Laurus Labs’ business model?
Ans. Laurus Labs manufactures APIs for antiretroviral (HIV/AIDS), oncology and other therapeutic areas. It also has a formulations business supplying finished dosage forms to emerging markets. Its contract manufacturing (CDMO) business serves as an additional revenue diversifier.